SCHEMBL191840

SCHEMBL191840

Fc1cccc(F)c1Oc1ccnc(Nc2nc(-c3ccsc3)cs2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 14/20 0.47
NPC1 O15118 14/20 0.47
MEN1 O00255 14/20 0.47
KMT2A Q03164 14/20 0.47
CASP3 P42574 4/20 0.47
SENP8 Q96LD8 4/20 0.47
SENP7 Q9BQF6 4/20 0.47
SENP6 Q9GZR1 4/20 0.47
GCK P35557 1/20 0.44
TRPV4 Q9HBA0 1/20 0.43
KCNN1 Q92952 2/20 0.43
KCNN2 Q9H2S1 2/20 0.43
KCNN3 Q9UGI6 2/20 0.43
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
NFKB1 P19838 2/20 0.42
MAPK1 P28482 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
HTT P42858 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190602 0.89 NPC1 (0.58) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL190433 0.89 RAB9A (0.55) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL191394 0.85 RAB9A (0.58) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL190426 0.84 KCNN1 (0.61) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL191689 0.81 GCK (0.52) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL191008 0.79 GCK (0.46) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL192191 0.79 GCK (0.47) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL191295 0.78 GCK (0.49) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL190863 0.78 GCK (0.49) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL191148 0.77 GCK (0.46) RAB9ANPC1MEN1KMT2ACASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 RAB9A 1808/4885NPC1 1862/4885MEN1 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.